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LETTER TO EDITOR
Bromelain inhibits SARS-CoV-2 infection via targeting
ACE-2, TMPRSS2, and spike protein
Dear Editor,
The new coronavirus, SARS-CoV-2, transmits rapidly from
human-to-human resulting in the ongoing pandemic.
SARS-CoV-2 infects angiotensin-converting enzyme 2
(ACE-2) expressing lung, heart, kidney, intestine, gall blad-
der, and testicular tissues of patients, leading to organ fail-
ure and sometimes death.1,2 Currently, COVID-19 patients
are treated with different agents, including favilavir,
remdesivir, chloroquine, hydroxychloroquine, lopinavir,
darunavir, and tocilizumab.3,4 However, the safety and
efficacy of those drugs against COVID-19 still need fur-
ther confirmation by randomized clinical trials. Hence,
there is an emergent need to repurpose the existing drugs
or develop new virus-based and host-based antivirals
against SARS-CoV-2. Bromelain is a cysteine protease iso-
lated from pineapple stem and is used as a dietary sup-
plement for treating patients with pain, inflammation,5
thrombosis,6 and cancer.7
Recently, studies have shown that SARS-CoV-2
homotrimeric viral spike protein (S1) binds to the Trans-
membrane Serine Protease 2 (TMPRSS2) primed host
cell’s receptor ACE-2 for initial entry, followed by S2-
mediated membrane fusion.8 Of several normal and
cancerous cells tested, VeroE6 and Calu-3 cells showed
ACE-2 protein expression (Fig. 1A), as well as a basal
level of TMPRSS2 protein (Fig. 1B). Since ACE-29 and
TMPRSS2 (UniProtKB-O15393) contains cysteine residues
with disulfide bonds to stabilize the protein structure,
we investigated the effect of bromelain on ACE-2 and
TMPRSS2 expression. Bromelain-induced a dose- and
time-dependent reduction of ACE-2 and TMPRSS2 expres-
sion in VeroE6 cells (Fig. 1C and D) but do not alter
ACE-2 expression in Calu-3 cells (Fig. 1E). However,
bromelain reduces the expression of TMPRSS2 in Calu-3
(Fig. 1E) and ACE-2 negative normal bronchial epithelial
(BEAS-2B) and lung adenocarcinoma (A549) cells (Fig. 1F
and G). Cysteine protease inhibitor (E-64) treatment
further confirmed that bromelain’s cysteine protease
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activity could cleave/reduce the expression of ACE-2 and
TMPRSS2 (Fig. 1H). Surface plasmon resonance (SPR)
analysis revealed that purified SARS-CoV-2 S-ectodomain
binds with ACE-2 in a concentration-dependent manner
and has a comparable binding affinity as control RBD
(Fig. 1I). The calculated molecular weight of the purified
S-ectodomain-GFP protein is ∼165 kDa; however, we
observed a higher molecular weight of S-ectodomain
(∼215 kDa), which may be due to heavy N- and O-linked
glycosylation (Fig. 1I intent). A serological assay showed a
significantly increased median fluorescent intensity (MFI)
of purified S-ectodomain with COVID-19 positive patients’
samples (Fig. 1J). These two results indicated that purified
S-ectodomain is a properly folded and functionally active
protein.
The S-ectodomain has 30 cysteine amino acids with
15 stabilizing disulfide bonds (UniProtKB: P0DTC2)
(Fig. 2A). The RBD domain alone has nine cysteine
residues, eight of which form four disulfide linkages.
Bromelain-induced a dose- and time-dependent cleavage
of S-ectodomain in Tni insect cell supernatant (Fig. 2B
and C) and purified S-ectodomain (Fig. 2D). Heat inacti-
vation and cysteine proteinase inhibitor (E-64) treatment
inhibited bromelain mediated digestion of S-ectodomain
(Fig. 2E and F). Further, SARS-CoV-2 with bromelain
treatment showed the loss of Spike protein on the viral sur-
face (Fig. 2G). Our docking studies between homotrimeric
(RBD containing chain A) S protein and stem bromelain
revealed that bromelain cleaves the S-protein equally
likely at the 131–166 (50.4%) and 617–649 (49.6%) disulfide
bonds (Fig. 2H). Though the catalytic site is not directly
engaged, protein–protein docking places the enzyme in
close proximity to these bonds. These results demonstrate
that bromelain’s cysteine protease activity is responsible
for the cleavage of host cells’ ACE-2 and SARS-CoV-2
S-protein.
Since bromelain digested ACE-2 and S-ectodomain, we
investigated the effect of bromelain on the interactions
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F IGURE 1 Bromelain inhibits ACE-2 and TMPRSS2 expression. (A and B) Immunoprobing of ACE-2 and TMPRSS2 expression in various
normal and cancerous cells. (C and D) Immunoblotting of ACE-2 and TMPRSS2 in VeroE6 cells treated with varying dose (19, 37, and 75 µg/ml
for 48 h) and time (75 µg/ml for 1–4 h), respectively. (E) Immunoblotting of ACE-2 and TMPRSS2 in Calu-3 cells treated with varying dose (19,
37, and 75 µg/ml for 48 h). (F and G) Immunoblotting of TMPRSS2 in BEAS-2B and A549 cells treated with varying dose (9.5 and 19 µg/ml
for 48 h). (H) ACE-2 and TMPRSS2 expression in bromelain (75 µg/ml) plus E-64 (4 µM) treated VeroE6 cells. β-Actin and GAPDH served as
a loading control. (I) SPR Max Resonance Units (RSU) at equilibrium as a function of the concentration of control RBD and S-ectodomain
using immobilized ACE-2. S-ectodomain-eGFP purified from Tni insect cells and showed ∼215 kDa molecular weight (intent; 1, mock control;
2, S-ectodomain-eGFP). (J) Luminex assay median fluorescent intensity (MFI) of S-ectodomain with COVID-19 positive (n = 6) and negative
(n = 6) patients’ samples.
of S-ectodomain and SARS-CoV-2 with VeroE6 cells.
Bromelain significantly reduced the binding of S-protein
to VeroE6 cells (Fig. 3A and B) and was further con-
firmed by cysteine protease inhibitor (E-64) treatment
(Fig. 3C). Interestingly, bromelain pre-treatment signif-
icantly decreased SARS-CoV-2 viral binding in VeroE6
cells (P = .0021) (Fig. 3D). Most importantly, VeroE6
cells or SARS-CoV-2 or both with bromelain reduces the
viral infection (Fig. 3E and F). Additionally, we found
significantly reduced SARS-CoV-2 viral RNA copies in
bromelain-treated VeroE6 (P = .0010) and Calu-3 (P =
.0099) cells (Fig. 3G and H, respectively). Collectively,
these results suggest that bromelain could inhibit SARS-
CoV-2 binding and infection in VeroE6 and Calu-3 cells.
Studies have demonstrated that SARS-CoV-2 S-protein has
high homology among other coronaviruses (76% identity
with SARS-CoV) with conserved cysteine amino acids
(UniProtKB: P59594). This indicates that bromelain may
be used as a broad antiviral agent against SARS-CoV-2 and
other related family members.
In conclusion, the currently used drugs against
SARS-CoV-2 have potential side effects. Vaccine
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F IGURE 2 Bromelain cleaves SARS-CoV-2 S-ectodomain. (A) Schematic representation of predicted cysteine amino acid position and
disulfide bridges in SARS-CoV-2 S-ectodomain. (B and C) Immunoblotting of S-ectodomain in bromelain-treated Tni insect cell supernatant
varying dose (5, 10, 15, 20, and 25 µg/mg of total protein) and time (25 µg/mg of total protein for 10–60 min), respectively. (D) Immunoprobing
of bromelain-treated purified S-ectodomain (1:10 ratio) with 30, 60, 120, and 240 min. (E and F) Immunoprobing of S-ectodomain in heat-
inactivated bromelain (80◦C/8 min) and bromelain (25 µg/mg of total protein) plus E-64 (1, 2, and 4 µM) treated Tni supernatant, respectively.
SimplyBlue-stained gel images of bromelain-treated Tni supernatant served as a loading control. (G) Negative-staining transmission-EM of
bromelain-treated (250 µg /ml, at 37◦C for 1.5 h) SARS-CoV-2. Viral particles treated with vehicle control (left) and bromelain (right). Scale bar
= 100 nm. Experiments were performed thrice, and a representative image is presented. (H) Representative conformation of bromelain (yellow
andmagenta) docked with the S protein (green) near the 131–166 (upper-left; closer view upper right) and 617–649 (lower-left; closer view lower
right) disulfide bridge
trials have started against COVID-19, but the host
immune response against SARS-CoV-2 is not fully
understood. It differs between individuals, and also
re-infection of individuals with SARS-CoV-2. For the
first time, our results demonstrate that bromelain can
inhibit SARS-CoV-2 infection via targeting ACE-2,
TMPRSS2, and SARS-CoV-2 S-protein. Also, thrombosis
development is a significant risk factor of multior-
gan failure and death in COVID-19 patients.10 Since
bromelain inhibits SARS-CoV-2 infection, and its pro-
found fibrinolytic activity 6 suggests that bromelain or
bromelain-rich pineapple could be used as an antivi-
ral against SARS-CoV-2 and future outbreaks of other
coronaviruses.
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F IGURE 3 Bromelain inhibits SARS-CoV-2 binding and infection. (A and B) Immunofluorescence and flow cytometry analysis of S-
ectodomain in vehicle- (PBS) and bromelain (75 µg/ml/2 h)-treated VeroE6 cells (n = 3), respectively. The mean fluorescent intensity was
measured by using FlowJo software. Experiments were performed twice, and one set of representative data is presented. Mean ± SD. (C)
Immunofluorescence of S-ectodomain in-vehicle, bromelain (75 µg/ml) with and without E-64 (4 µM)-treated VeroE6 cells (n = 3) for 2 h.
Nuclei were stained with DAPI. Scale bar = 20 µm. (D) qRT-PCR analysis of SARS-CoV-2 RNA in vehicle and bromelain pre-treated VeroE6
cells. The Cq values were graphically represented. Mean ± SD (n = 3). Immunofluorescence analysis of SARS-CoV-2 in bromelain pre-treated
VeroE6 cells (75 µg/ml/2 h) (n = 6) (E), bromelain pre-treated SARS-CoV-2 (75 µg/ml/1 h) and bromelain co-treated SARS-CoV-2 plus VeroE6
cells (75 µg/ml/1 h) (n = 4) (F). Scale bar = 50 µm. Nuclei were stained with Hoechst 33342. (G and H) qRT-PCR analysis of SARS-CoV-2 RNA
infected bromelain-treated VeroE6 and Calu-3 cell culture supernatants, respectively (n= 3). The Cq values were graphically represented.Mean
± SD (n = 3). P < .05 was considered statistically significant with an unpaired Student’s t-test
LETTER TO EDITOR 5 of 6
ACKNOWLEDGMENTS
We thank Dr. Kenneth Cowan, Dr. Dalia ElGamal, and
Melody J. Morwitzer (UNMC, USA) for their strong sup-
port and help. We also thank Elizabeth Coyle (FDA, USA)
and Silvie Muschter (Robert Koch Institute, Germany) for
their technical assistance. The authors on this manuscript
are supported in part by the National Cancer Institute
(NIH) grant (R01CA208108), and by the Fred and Pamela
Buffett Cancer Center start-up funds (to P.R), and the Fred
and Pamela Buffett NCI Cancer Center Support Grant
(P30CA036727) (to G.E.O.B.).
CONFL ICT OF INTEREST
Satish Sagar and Prakash Radhakrishnan have ownership
interest (including patents) in a pending patent.
ETH ICS APPROVAL AND CONSENT TO
PART IC IPATE
The institutional review board (IRB) of the University of
Nebraska Medical Center approved clinical samples used
in this study.
AUTH OR CONTRIBUT IONS
Prakash Radhakrishnan conceived the idea; Surender
Khurana, St. Patrick M. Reid, Gloria E. O. Borgstahl, and
Prakash Radhakrishnan designed research; Satish Sagar,
Ashok Kumar Rathinavel, William E. Lutz, Lucas R. Stru-
ble, St. Patrick M. Reid, Tobias Hoffmann, and Mara J.
Broadhurst performed research; Nitish Kumar Mishra,
Chittibabu Guda, Nicholas Y. Palermo, and Kenneth W.
Bayles contributed new reagents/analytic tools; Satish
Sagar, Ashok Kumar Rathinavel, Andy T. Schnaubelt, Glo-
ria E. O. Borgstahl, St. Patrick M. Reid, and Prakash Rad-
hakrishnan analyzed data; Gloria E. O. Borgstahl, and
Prakash Radhakrishnan wrote the paper.
DATA AVAILAB IL ITY STATEMENT














St. Patrick M. Reid3
Gloria E. O. Borgstahl1,5
Prakash Radhakrishnan1,3,4,5
1 Eppley Institute for Research in Cancer and Allied
Diseases, University of Nebraska Medical Center, Omaha,
Nebraska, USA
2 Division of Viral Products, Center for Biologics Evaluation
and Research (CBER), FDA, Silver Spring, Maryland, USA
3 Department of Pathology and Microbiology, University of
Nebraska Medical Center, Omaha, Nebraska, USA
4 Department of Genetics, Cell Biology and Anatomy,
University of Nebraska Medical Center, Omaha, Nebraska,
USA
5 Fred & Pamela Buffett Cancer Center, University of
Nebraska Medical Center, Omaha, Nebraska, USA
6 Computational Chemistry Core, University of Nebraska
Medical Center, Omaha, Nebraska, USA
7 Advanced Light and Electron Microscopy, Centre for
Biological Threats and Special Pathogens 4 (ZBS 4), Robert
Koch Institute, Berlin, Germany
Correspondence
Prakash Radhakrishnan, Eppley Institute for Research in
Cancer and Allied Diseases, University of Nebraska






1. Zaim S, Chong JH, Sankaranarayanan V, Harky A. COVID-
19 and multiorgan response. Curr Probl Cardiol. 2020;45(8):
100618.
2. Fan C, Li K, Ding Y, Lu W, Wang J. ACE2 expression in kid-
ney and testis may cause kidney and testis damage after 2019-
nCoV infection.MedRxiv. 2020. https://doi.org/10.1101/2020.02.
12.20022418.
3. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus dis-
ease 2019 (COVID-19). Drug Discov Ther. 2020;14(1):58-60.
4. Abd El-Aziz TM, Stockand JD. Recent progress and challenges
in drug development against COVID-19 coronavirus (SARS-
CoV-2): an update on the status. Infect Genet Evol. 2020;83. https:
//doi.org/10.1016/j.meegid.2020.104327.
5. MajidOW,Al-Mashhadani BA. Perioperative bromelain reduces
pain and swelling and improves quality of life measures
after mandibular third molar surgery: a randomized, double-
blind, placebo-controlled clinical trial. J Oral Maxillofac Surg.
2014;72(6):1043-1048.
6. Felton GE. Fibrinolytic and antithrombotic action of bromelain
may eliminate thrombosis in heart patients. Med Hypotheses.
1980;6(11):1123-1133.
6 of 6 LETTER TO EDITOR
7. Valle SJ, Akhter J, Mekkawy AH, et al. A novel treatment
of bromelain and acetylcysteine (BromAc) in patients with
peritoneal mucinous tumours: A phase I first in man study. Eur
J Surg Oncol. 2019;31. doi:10.1016/j.ejso.2019.10.033.
8. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2
cell entry depends on ACE2 and TMPRSS2 and is blocked by a
clinically proven protease inhibitor. Cell. 2020;181(2):271-280.e8.
9. Towler P, Staker B, Prasad SG, et al. ACE2X-ray structures reveal
a large hinge-bending motion important for inhibitor binding
and catalysis. J Biol Chem. 2004;279(17):17996-18007.
10. Bilaloglu S, Aphinyanaphongs Y, Jones S, Iturrate E, Hochman
J, Berger JS. Thrombosis in hospitalized patients with COVID-19
in a New York City health system. JAMA. 2020;324(8):799-801.
SUPPORT ING INFORMATION
Additional supporting information may be found online
in the Supporting Information section at the end of the
article.
